Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins

Obesity

Volumn 22, Issue 8, 2014, Pages 1854-1859

  Matikainen, Niina ^a,b   Adiels, Martin ^c   Söderlund, Sanni ^a   Stennabb, Sanna ^a,b   Ahola, Tytti ^a   Hakkarainen, Antti ^a   Borén, Jan ^c   Taskinen, Marja Riitta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; LIPOPROTEIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; LIPOPROTEIN TRIGLYCERIDE;

ADULT; ARTICLE; BODY MASS; CLINICAL EVALUATION; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DIET RESTRICTION; ENZYME ACTIVITY; FATTY ACID OXIDATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID DIET; LIPID OXIDATION; LIPOGENESIS; MALE; POSTPRANDIAL STATE; RISK FACTOR; BIOSYNTHESIS; BLOOD; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

3-HYDROXYBUTYRIC ACID; ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEIN C-III; FASTING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEINS; LIVER; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 84905034028     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20781     Document Type: Article

References (32)

1. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61.
2. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A,. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
3. Karpe F,. Chylomicron production as a feature of atherogenic lipoproteins. Curr Opin Lipidol 2012; 23: 398-99.
4. Zheng C,. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol 2014; 25: 35-39.
5. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR,. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Related Metab Disord J Int Assoc Study Obes 1998; 22: 414-23.
6. Zilversmit DB,. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 1973; 33: 633-38.
7. Cohn JS, Johnson EJ, Millar JS, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993; 34: 2033-40.
8. Adiels M, Matikainen N, Westerbacka J, et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012; 222: 222-28.
9. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-65.
10. Timlin MT, Parks EJ,. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 2005; 81: 35-42.
11. Schwarz JM, Linfoot P, Dare D, Aghajanian K,. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43-50.
12. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ,. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig 2005; 115: 1343-51.
13. Lodhi IJ, Wei X, Semenkovich CF,. Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol Metab 2011; 22: 1-8.
14. Hodson L, Frayn KN,. Hepatic fatty acid partitioning. Curr Opin Lipidol 2011; 22: 216-24.
15. Matikainen N, Manttari S, Westerbacka J, et al. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007; 92: 3052-59.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
17. Lundbom J, Hakkarainen A, Soderlund S, Westerbacka J, Lundbom N, Taskinen MR,. Long-TE 1H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. NMR Biomed 2011; 24: 238-45.
18. Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscl Thromb Vasc Biol 2011; 31: 2144-50.
19. Huttunen JK, Ehnholm C, Kinnunen PKJ, Nikkilä EA,. An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975; 63: 335-47.
20. Kawano Y, Cohen DE,. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013; 48: 434-41.
21. Barrows BR, Parks EJ,. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 2006; 91: 1446-52.
22. Chong MF-F, Fielding BA, Frayn KN,. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr 2007; 85: 1511-20.
23. Parks EJ, Skokan LE, Timlin MT, Dingfelder CS,. Dietary sugars stimulate fatty acid synthesis in adults. J Nutr 2008; 138: 1039-46.
24. McGarry JD, Mannaerts GP, Foster DW,. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Investig 1977; 60: 265-70.
25. Esser V, Britton CH, Weis BC, Foster DW, McGarry JD,. Cloning, sequencing, and expression of a cDNA encoding rat liver carnitine palmitoyltransferase I. Direct evidence that a single polypeptide is involved in inhibitor interaction and catalytic function. J Biol Chem 1993; 268: 5817-22.
26. McGarry JD,. Travels with carnitine palmitoyltransferase I: from liver to germ cell with stops in between. Biochem Soc Trans 2001; 29: 241-45.
27. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M,. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004; 432: 1027-32.
28. Benhamed F, Denechaud PD, Lemoine M, et al the lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Investig 2012; 122: 2176-94.
29. Eissing L, Scherer T, Todter K, et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat Commun 2013; 4: 1528.
30. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B,. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013; 58: 1497-1507.
31. Sundaram M, Yao Z,. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) 2010; 7: 35.
32. Kahri J, Fruchart-Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR, the increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity. Diabetes Care 2007; 30: 2083-085.